Addex Convenes Annual General Meeting 2024

Core Viewpoint - Addex Therapeutics is set to hold its 2024 Annual General Meeting on June 28, 2024, focusing on key corporate governance matters and financial approvals for the year 2023 [1] Group 1: Annual General Meeting Agenda - Approval of the Annual Report, Annual Financial Statements, and Consolidated Financial Statements for the business year 2023 [2] - Consultative vote on the Compensation Report for the business year 2023 [2] - Re-elections of members of the Board of Directors, including Vincent Lawton as Chairman [2][3] - Amendments to the Articles of Association, including an increase in the capital band and conditional share capital [2][3] Group 2: Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The lead drug candidate, ADX71149, has completed a Phase 2 clinical study for epilepsy, while dipraglurant is under evaluation for dyskinesia associated with Parkinson's disease [4] - Addex has partnerships with Indivior for GABAB PAM programs and holds a 20% share in Neurosterix LLC, which is advancing multiple allosteric modulator programs [4]